Added to YB: 2025-12-30
Pitch date: 2025-12-28
SLNO [bullish]
Soleno Therapeutics, Inc.
+9.31%
current return
Author Info
No bio for this author
Company Info
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Market Cap
$2.2B
Pitch Price
$47.80
Price Target
130.00 (+149%)
Dividend
N/A
EV/EBITDA
97.60
P/E
105.15
EV/Sales
9.19
Sector
Biotechnology
Category
growth
Soleno Therapeutics (NASDAQ: SLNO)
SLNO: FDA-approved VYKAT XR for PWS hyperphagia shows strong Q3 launch w/ $66M revenue (vs $46M est), 764 treated patients, 8% discontinuation. Only approved therapy in 12-22K US PWS market. Weight-based dosing creates higher real-world revenues. $130 target on DCF, peak sales est $3.2B by 2033.
Read full article (43 min)